________________________________ Substance Use Disorders and Pain Management: MATE Act Training
51. Compared with methadone, buprenorphine has a A) lower risk of overdose. B) shorter duration of action. C) more severe withdrawal syndrome following cessation. D) All of the above 52. Buprenorphine is most effective at a dose of A) 2 mg. B) 5 mg. C) 10 mg. D) 12 mg or greater. 53. Duration of treatment with varenicline tartrate is A) 4 weeks. B) 8 weeks.
57. Which of the following ethical issue should be considered when caring for patients with substance use disorders?
A) Confidentiality B) Access to services C) Informed consent D) All of the above
58. When opioids are used for acute pain, clinicians should prescribe A) the highest safe dose. B) extended-release opioids. C) a quantity no greater than that needed for the expected duration of severe pain. D) All of the above 59. In a survey of oncologists regarding end-of-life pain management, what were two of the most important barriers to effective pain relief? A) Patient reluctance to take opioids or to report pain B) Clinician reluctance to prescribe opioids or believe pain reports C) Desire to be a “good” patient and concern about the high cost of medications D) Anxiety about disease progression and unpleasant side effects from pain medications 60. A patient prescribed opioids for chronic pain who is 65 years of age and displays high levels of pain acceptance and active coping strategies is considered at what level of risk for developing problematic opioid behavioral responses? A) Low B) Medium C) High D) Severe 61. The Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R) A) consists of 5 items. B) is patient administered. C) diagnoses depression in the past month. D) assesses the likelihood of current substance abuse.
C) 12 weeks. D) 24 weeks.
54. Which of the following treatment approaches is recommended by SAMHSA for the management of patients with comorbid opioid and alcohol dependence? A) FDA-approved pharmacotherapy and counseling B) Contingency management together with FDA- approved pharmacotherapy and counseling C) Twelve-step facilitation therapy together with FDA-approved pharmacotherapy and counseling D) None of the above 55. Which of the following statements regarding comorbid mental and substance use disorders is FALSE? A) In the United States, 1 million adults have cooccurring mental and substance use disorders. B) No specific combinations of mental and substance use disorders are defined uniquely as co-occurring disorders. C) Patients with comorbid disorders demonstrate poorer treatment adherence and higher rates of treatment dropout than those without mental illness. D) Integrated treatment for comorbid drug use disorder and mental illness has been found to be consistently superior compared with separate treatment of each diagnosis. 56. Treatment of comorbid mental and substance use disorders should initially focus on A) stabilization of the patient’s substance use disorder. B) stabilization of the patient’s mental health disorder. C) a goal of six to nine weeks abstinence before addressing comorbidities. D) any mental disorder symptoms that appear to resolve during abstinence.
Test questions continue on next page
65
MDNJ1525
Powered by FlippingBook